Zosano Appoints Georgia Erbez as Chief Business Officer
08 9월 2016 - 9:30PM
Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company
focusing on providing rapid symptom relief to patients using the
Company’s proprietary transdermal delivery system, today announced
the appointment of Ms. Georgia Erbez as its Chief Business Officer,
effective September 8, 2016. Ms. Erbez will continue to serve
as Zosano’s Interim Chief Financial Officer.
“We are excited to appoint Georgia to the Chief Business Officer
position. Her extensive experience in senior management roles in
the healthcare sector will be instrumental as we continue to
advance the development of M207 for the treatment of acute
migraine,” commented Konstantinos Alataris, PhD, President and
Chief Executive Officer of Zosano Pharma.
Ms. Erbez has served as Interim Chief Financial Officer of
Zosano since June 2016 and through the years, has provided
financial and strategic consultancy to multiple biotechnology
companies. Previous experience includes serving as Chief Financial
Officer and Executive Vice President of Asterias Biotherapeutics,
Inc. and Chief Financial Officer, Secretary and Treasurer of Raptor
Pharmaceuticals, where she helped to navigate the company through a
growth period that included its first drug approval and subsequent
commercial launch. Prior to Raptor, Ms. Erbez was a Managing
Director, Healthcare Investment Banking at Collins Stewart, a
senior level investment banker at Beal Advisors, Jeffries &
Company, Inc. and Cowen and Company. She has also held
positions at the investment banks Hambrecht & Quist and Alex,
Brown & Sons Inc. Ms. Erbez received a Bachelor of
Arts degree, International Relations from the University of
California at Davis.
About Zosano Pharma
Zosano Pharma Corporation is an emerging CNS company focusing on
providing rapid symptom relief to patients using known therapeutics
and altering their delivery profile using the Company’s proprietary
transdermal delivery system. The Company’s goal is to make
transdermal drug delivery a standard of care for delivering drugs
requiring fast onset of action. Zosano Pharma has developed its
proprietary transdermal delivery system to administer novel
formulations of existing drugs through the skin for the treatment
of a variety of indications. The Company believes that its
transdermal delivery system offers rapid and consistent drug
delivery combined with ease of use. The Company is focused on
developing products that deliver established molecules with known
safety and efficacy profiles for markets where patients remain
underserved by existing therapies. Zosano Pharma anticipates
that many of its current and future development programs may enable
the Company to utilize a regulatory pathway that would streamline
clinical development and accelerate the path towards
commercialization. Learn more at www.zosanopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
the timing of expected clinical development milestones, including
the timeline for pivotal efficacy data, our ability to obtain
necessary regulatory approvals and other future events and
expectations. Readers are urged to consider statements that include
the words "expects," "continues," "believes," "potential," “goal,”
"may," "will," "would," "could," "should," "might," "estimates,"
"projects," "plans," "anticipates," "intends," "forecast,"
"designed," "approximately" or the negative of those words or other
comparable words to be uncertain and forward-looking. These
statements are subject to risks and uncertainties that are
difficult to predict and actual outcomes may differ materially.
These include risks and uncertainties, without limitation,
associated with the process of discovering, developing and
commercializing products that are safe and effective for use as
human therapeutics, risks inherent in the effort to build a
business around such products and other risks and uncertainties
described under the heading "Risk Factors" in our 2015 Annual
Report on Form 10-K, as filed with the Securities Exchange
Commission on March 29, 2016. Although we believe that the
expectations reflected in these forward-looking statements are
reasonable, we cannot in any way guarantee that the future results,
level of activity, performance or events and circumstances
reflected in forward-looking statements will be achieved or occur.
All forward-looking statements are based on information currently
available to Zosano and Zosano assumes no obligation to update any
such forward-looking statements.
Zosano Contact:
Konstantinos Alataris, Ph.D.
Chief Executive Officer
510-745-1200
Investor Contact:
Jamien Jones
Blueprint Life Science Group
415-375-3340 x 5
jjones@bplifescience.com
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024